ABSTRACT
Our study evaluates the molecular and clinical effects of genetic ancestry in African and South Asian women compared to European using a combined cohort of 7,253 breast cancer patients available from four data sources: the 100,000 Genomes Project (UK), The Cancer Genome Atlas (US), the Breast Cancer Now Biobank (UK) and Genes & Health (UK).
We find that non-European breast cancer patients present significantly earlier and die at a younger age. The African ancestry group has an increased prevalence of higher grade and hormone receptor negative disease. The South Asian group shows tendency towards lower stage at diagnosis and lower tumour mutational burden. We observe significant differences and similarities in the somatic mutational landscape. We identify differences in germline mutation rates in genes used in genetic testing and others implicated in breast cancer predisposition. Potential therapeutic targets are differentially mutated. We report a higher propensity for homologous recombination deficiency serving as a potential therapy response indicator.
Although precision oncology holds the promise of revolutionising healthcare, it could exacerbate the disparities it seeks to eradicate unless research biases are addressed. We harness multimodal data to improve our understanding of ancestry-associated differences in breast cancer and highlight opportunities to advance health equity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Barts Charity (grant code MGU0504) and Barts NIHR BRC (grant code BTXH1A1R). BCN Biobank is funded by the Breast Cancer Now charity (grant code TB2022BAR). This work forms part of the research portfolio of the National Institute for Health and Care Research Barts Biomedical Research Centre (NIHR203330).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
East of England - Cambridge Central Research Ethics Committee gave ethical approval for the Breast Cancer Now Biobank (REC reference: 23-EE-0229). Genomics England Clinical Interpretation Partnership (GECIP) gave approval for this work reference 643) to use Genomics England data. Genes & Health gave approval to this work reference S00087 to use the Genes & Health data. The Data Access Committee for The Cancer Genome Atlas (TCGA) gave approval for this work reference dbGaP project #15970 to use TCGA data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† The first 2 authors should be regarded as joint First Authors.
Update the metadata of the supplementary information. No text updated from previous version
Data Availability
Genomic and phenotypic data for the 100KGP study participants are available through the Genomics England Research Environment via application at https://www.genomicsengland.co.uk/research/academic/join-gecip. The clinical data and donor ancestry calls for the TCGA cohort used in this study are available from the supplemental information (Table S1) of Carrot-Zhang et al.6 Additional clinical and genomic data for the TCGA BRCA cohort were accessed from the Genomics Data Commons Data Portal.44
Clinical data and specimens of dually consented patients are available from the BCN Biobank on application to the Tissue Bank, and clinical and molecular data from G&H is available through the Genes and Health Research Environment via application at https://www.genesandhealth.org/research/scientists-using-genes-health-scientific-research.
